Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant

被引:152
|
作者
Al-Mashhadi, Rozh H. [1 ,2 ]
Sorensen, Charlotte B. [3 ]
Kragh, Peter M. [4 ]
Christoffersen, Christina [5 ]
Mortensen, Martin B. [1 ,2 ]
Tolbod, Lars P. [6 ,7 ]
Thim, Troels [1 ,2 ]
Du, Yutao [4 ]
Li, Juan [4 ]
Liu, Ying [4 ]
Moldt, Brian [3 ]
Schmidt, Mette [8 ]
Vajta, Gabor [4 ,9 ]
Larsen, Torben [4 ]
Purup, Stig [4 ]
Bolund, Lars [3 ,10 ]
Nielsen, Lars B. [5 ,11 ]
Callesen, Henrik [4 ]
Falk, Erling [1 ,2 ]
Mikkelsen, Jacob Giehm [3 ]
Bentzon, Jacob F. [1 ,2 ]
机构
[1] Aarhus Univ, Aarhus Univ Hosp, Dept Cardiol, DK-8200 Aarhus, Denmark
[2] Aarhus Univ, Dept Clin Med, DK-8200 Aarhus N, Denmark
[3] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark
[4] Aarhus Univ, Dept Anim Sci, DK-8830 Tjele, Denmark
[5] Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[6] Aarhus Univ Hosp, Dept Nucl Med, DK-8200 Aarhus N, Denmark
[7] Aarhus Univ Hosp, PET Ctr, DK-8200 Aarhus N, Denmark
[8] Univ Copenhagen, Dept Large Anim Sci, DK-1870 Frederiksberg C, Denmark
[9] Cent Queensland Univ, Rockhampton, Qld 4702, Australia
[10] Beishan Ind Zone, BGI Shenzhen, BGI HuaDa JiYin, Shenzhen 518083, Peoples R China
[11] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen N, Denmark
关键词
POSITRON-EMISSION-TOMOGRAPHY; SLEEPING-BEAUTY TRANSPOSASE; CORONARY ATHEROSCLEROSIS; PLAQUE INFLAMMATION; MAMMALIAN-CELLS; BINDING DOMAIN; DEFICIENT MICE; DISEASE; EXPRESSION; LESIONS;
D O I
10.1126/scitranslmed.3004853
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lack of animal models with human-like size and pathology hampers translational research in atherosclerosis. Mouse models are missing central features of human atherosclerosis and are too small for intravascular procedures and imaging. Modeling the disease in minipigs may overcome these limitations, but it has proven difficult to induce rapid atherosclerosis in normal pigs by high-fat feeding alone, and genetically modified models similar to those created in mice are not available. D374Y gain-of-function mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene cause severe autosomal dominant hypercholesterolemia and accelerates atherosclerosis in humans. Using Sleeping Beauty DNA transposition and cloning by somatic cell nuclear transfer, we created Yucatan minipigs with liver-specific expression of human D374Y-PCSK9. D374Y-PCSK9 transgenic pigs displayed reduced hepatic low-density lipoprotein (LDL) receptor levels, impaired LDL clearance, severe hypercholesterolemia, and spontaneous development of progressive atherosclerotic lesions that could be visualized by noninvasive imaging. This model should prove useful for several types of translational research in atherosclerosis.
引用
收藏
页数:10
相关论文
共 45 条
  • [11] Prevalence, Clinical Characteristics and Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia Patients With Double-Heterozygous Mutation of LDLR and PCSK9 Gain-Of-Function Mutation
    Doi, Takahito
    Hori, Mika
    Harada-Shiba, Mariko
    Kataoka, Yu
    Nishikawa, Ryo
    Tsuda, Kosuke
    Nishimura, Kunihiro
    Ogura, Masatsune
    Noguchi, Teruo
    Yasuda, Satoshi
    CIRCULATION, 2018, 138
  • [12] Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia
    Di Taranto, Maria Donata
    Benito-Vicente, Asier
    Giacobbe, Carola
    Uribe, Kepa Belloso
    Rubba, Paolo
    Etxebarria, Aitor
    Guardamagna, Ornella
    Gentile, Marco
    Martin, Cesar
    Fortunato, Giuliana
    SCIENTIFIC REPORTS, 2017, 7
  • [13] EFFICACY OF EVOLOCUMAB (AMG 145) IN PATIENTSWITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
    Harada-Shiba, M.
    Kishimoto, I.
    Makino, H.
    Ogura, M.
    Kurtz, C.
    Honarpour, N.
    Xu, F.
    Wasserman, S. M.
    Watts, G. F.
    ATHEROSCLEROSIS, 2014, 235 (02) : E11 - E11
  • [14] Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations
    Hopkins, P. N.
    Krempf, M.
    Bruckert, E.
    Luc, G.
    Donahue, S.
    Yang, F.
    Zhang, Y.
    Dicioccio, A. T.
    EUROPEAN HEART JOURNAL, 2018, 39 : 49 - 49
  • [15] Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
    Hopkins, Paul N.
    Defesche, Joep
    Fouchier, Sigrid W.
    Bruckert, Eric
    Luc, Gerald
    Cariou, Bertrand
    Sjouke, Barbara
    Leren, Trond P.
    Harada-Shiba, Mariko
    Mabuchi, Hiroshi
    Rabes, Jean-Pierre
    Carrie, Alain
    van Heyningen, Charles
    Carreau, Valerie
    Farnier, Michel
    Teoh, Yee P.
    Bourbon, Mafalda
    Kawashiri, Masa-aki
    Nohara, Atsushi
    Soran, Handrean
    Marais, A. David
    Tada, Hayato
    Abifadel, Marianne
    Boileau, Catherine
    Chanu, Bernard
    Katsuda, Shoji
    Kishimoto, Ichiro
    Lambert, Gilles
    Makino, Hisashi
    Miyamoto, Yoshihiro
    Pichelin, Matthieu
    Yagi, Kunimasa
    Yamagishi, Masakazu
    Zair, Yassine
    Mellis, Scott
    Yancopoulos, George D.
    Stahl, Neil
    Mendoza, Johanna
    Du, Yunling
    Hamon, Sara
    Krempf, Michel
    Swergold, Gary D.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2015, 8 (06) : 823 - 831
  • [16] Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis
    Shaik, Noor Ahmad
    Al-Shehri, Najla
    Athar, Mohammad
    Awan, Ahmed
    Khalili, Mariam
    Al Mahadi, Hadiah Bassam
    Hejazy, Gehan
    Saadah, Omar I. I.
    Al-Harthi, Sameer Eida
    Elango, Ramu
    Banaganapalli, Babajan
    Alefishat, Eman
    Awan, Zuhier
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [17] Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidaemias
    Terentes-Printzios, D.
    Koutagiar, I.
    Vlachopoulos, C.
    Skoumas, I.
    Rigatou, A.
    Miliou, A.
    Skliros, N. P.
    Pantou, S.
    Filis, K.
    Tousoulis, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 81 - 81
  • [18] Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias
    Vlachopoulos, Charalambos
    Koutagiar, Iosif
    Terentes-Printzios, Dimitrios
    Skoumas, Ioannis
    Rigatou, Angeliki
    Miliou, Antigoni
    Skliros, Alexandros-Nikitas
    Pantou, Stavroula
    Filis, Kostantinos
    Tousoulis, Dimitrios
    HELLENIC JOURNAL OF CARDIOLOGY, 2019, 60 (02) : 124 - 128
  • [19] The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9
    Sanchez-Hernandez, Rosa M.
    Di Taranto, Maria Donata
    Benito-Vicente, Asier
    Uribe, Kepa B.
    Lamiquiz-Moneo, Itziar
    Larrea-Sebal, Asier
    Jebari, Shifa
    Galicia-Garcia, Unai
    Javier Novoa, F.
    Boronat, Mauro
    Wagner, Ana M.
    Civeira, Fernando
    Martin, Cesar
    Fortunato, Giuliana
    ATHEROSCLEROSIS, 2019, 289 : 162 - 172
  • [20] A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification
    Goettsch, Claudia
    Hutcheson, Joshua D.
    Hagita, Sumihiko
    Rogers, Maximillian A.
    Creager, Michael D.
    Tan Pham
    Choi, Jung
    Mlynarchik, Andrew K.
    Pieper, Brett
    Kjolby, Mads
    Aikawa, Masanori
    Aikawa, Elena
    ATHEROSCLEROSIS, 2016, 251 : 109 - 118